5WMA

N-terminal bromodomain of BRD4 in complex with PLX5981


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.40 Å
  • R-Value Free: 0.176 
  • R-Value Work: 0.146 
  • R-Value Observed: 0.148 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer, H.G.El-Gamal, D.Powell, B.Hing, Z.A.Blachly, J.S.Harrington, B.Mitchell, S.Grieselhuber, N.R.Williams, K.Lai, T.H.Alinari, L.Baiocchi, R.A.Brinton, L.Baskin, E.Cannon, M.Beaver, L.Goettl, V.M.Lucas, D.M.Woyach, J.A.Sampath, D.Lehman, A.M.Yu, L.Zhang, J.Ma, Y.Zhang, Y.Spevak, W.Shi, S.Severson, P.Shellooe, R.Carias, H.Tsang, G.Dong, K.Ewing, T.Marimuthu, A.Tantoy, C.Walters, J.Sanftner, L.Rezaei, H.Nespi, M.Matusow, B.Habets, G.Ibrahim, P.Zhang, C.Mathe, E.A.Bollag, G.Byrd, J.C.Lapalombella, R.

(2018) Cancer Discov 8: 458-477

  • DOI: 10.1158/2159-8290.CD-17-0902
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpresse ...

    Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved in pathogenesis of chronic lymphocytic leukemia (CLL). BRD4 is overexpressed in CLL and is enriched proximal to genes upregulated or de novo expressed in CLL with known functions in disease pathogenesis and progression. These genes, including key members of the B-cell receptor (BCR) signaling pathway, provide a rationale for this therapeutic approach to identify new targets in alternative types of cancer. Additionally, we describe PLX51107, a structurally distinct BET inhibitor with novel in vitro and in vivo pharmacologic properties that emulates or exceeds the efficacy of BCR signaling agents in preclinical models of CLL. Herein, the discovery of the involvement of BRD4 in the core CLL transcriptional program provides a compelling rationale for clinical investigation of PLX51107 as epigenetic therapy in CLL and application of BRD4 profiling in other cancers. Significance: To date, functional studies of BRD4 in CLL are lacking. Through integrated genomic, functional, and pharmacologic analyses, we uncover the existence of BRD4-regulated core CLL transcriptional programs and present preclinical proof-of-concept studies validating BET inhibition as an epigenetic approach to target BCR signaling in CLL. Cancer Discov; 8(4); 458-77. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 371 .


    Organizational Affiliation

    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, Ohio. rosa.lapalombella@osumc.edu john.byrd@osumc.edu.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Bromodomain-containing protein 4
A
127Homo sapiensMutation(s): 0 
Gene Names: BRD4HUNK1
Find proteins for O60885 (Homo sapiens)
Go to UniProtKB:  O60885
NIH Common Fund Data Resources
PHAROS  O60885
Protein Feature View
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
6JC
Query on 6JC

Download CCD File 
A
5-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridine
C12 H11 N3 O
UKELRNSNPZHDOM-UHFFFAOYSA-N
 Ligand Interaction
EDO
Query on EDO

Download CCD File 
A
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.40 Å
  • R-Value Free: 0.176 
  • R-Value Work: 0.146 
  • R-Value Observed: 0.148 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 37.226α = 90
b = 44.47β = 90
c = 78.311γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
SCALEPACKdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2017-07-28 
  • Released Date: 2018-08-01 
  • Deposition Author(s): Zhang, Y.

Revision History 

  • Version 1.0: 2018-08-01
    Type: Initial release
  • Version 1.1: 2019-02-13
    Changes: Data collection, Database references